Fig. 4From: A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosisCalmagen® cream and lotion met secondary endpoint: IGA Response. Summary IGA response of tinea (a) and onychomycosis (b) subjects. N: Number of subjectsBack to article page